Compound targets essential viral enzyme and prevents replication in cells
A scanning electron microscope image showing SARS-CoV-2 (round gold objects), the virus that causes COVID-19, emerging from the surface of cells cultured in the lab. New research suggests that the experimental drug TEMPOL may be a promising oral antiviral treatment for COVID-19. The virus shown was isolated from a patient in the United States. The image was captured and colorized at NIAID s Rocky Mountain Laboratories in Hamilton, Montana.
Image: National Institute of Allergy and Infectious Diseases
A potential new antiviral drug for COVID-19
Linda H. Huynh and Sam Sholtis
June 03, 2021
A scanning electron microscope image showing SARS-CoV-2 (round gold objects), the virus that causes COVID-19, emerging from the surface of cells cultured.
Date Time
Researchers Use Big Data to Assess Seizure Burden and Improve Outcomes in Pediatric Epilepsy Patients
Researchers at Children’s Hospital of Philadelphia (CHOP) have demonstrated how to use standardized reporting of clinical data for seizures caused by a variety of neurological disorders, providing fundamental baseline information that can determine what methods work best for keeping seizures under control. The findings were published today in the journal Epilepsia.
In order to make improvements in epilepsy care, clinicians need a reliable and efficient method to measure outcomes. While Electronic Medical Records (EMR) are being used more frequently for research and quality improvement, important epilepsy outcome measures such as seizure frequency or quality of life are not documented in a standardized way that enables researchers to process large-scale data on the subject.
Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional.
A new study led by researchers at Washington State University has identified a protein that could be the key to improving treatment outcomes after a heart attack. Published in the Journal of Biological Chemistry, it suggests that protein kinase A (PKA) plays a role in heart muscle cell necrosis, a major type of cell death that commonly occurs after reperfusion therapy, the treatment used to unblock arteries and restore blood flow after a heart attack.